Telomir Pharmaceuticals (TELO) Cash & Equivalents (2022 - 2026)

Telomir Pharmaceuticals has reported Cash & Equivalents for 4 years, with the latest figure at $7.3 million in Q4 2025.

• Quarterly Cash & Equivalents rose 475.51% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 475.51% YoY) and the FY2025 annual result came in at $7.3 million, up 475.51% from the prior year.
• Cash & Equivalents was little changed at $7.3 million in Q4 2025 per TELO's latest filing, from $7.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $7.3 million in Q3 2025 and troughed at $1231.0 in Q4 2023.
• A 4-year average of $1.8 million and a median of $754323.0 in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 182523.13% in 2024, then sank 87.79% in 2025.
• Over 4 years, Cash & Equivalents stood at $1419.0 in 2022, then dropped by 13.25% to $1231.0 in 2023, then jumped by 102753.86% to $1.3 million in 2024, then jumped by 475.51% to $7.3 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.3 million, $7.3 million, and $754323.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.